1040 related articles for article (PubMed ID: 28739779)
1.
Pang Y; Zong Z; Huo F; Jing W; Ma Y; Dong L; Li Y; Zhao L; Fu Y; Huang H
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779
[TBL] [Abstract][Full Text] [Related]
2. No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis.
Pang Y; Jing W; Lu J; Zong Z; Huo F; Dong L; Dai G; Li Y; Huang H; Chu N
Diagn Microbiol Infect Dis; 2019 Aug; 94(4):361-364. PubMed ID: 30876684
[TBL] [Abstract][Full Text] [Related]
3. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
Yang JS; Kim KJ; Choi H; Lee SH
Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
[TBL] [Abstract][Full Text] [Related]
4. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition.
Yao C; Guo H; Li Q; Zhang X; Shang Y; Li T; Wang Y; Xue Z; Wang L; Li L; Pang Y
Antimicrob Resist Infect Control; 2021 Aug; 10(1):126. PubMed ID: 34446095
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China.
Zheng H; He W; Jiao W; Xia H; Sun L; Wang S; Xiao J; Ou X; Zhao Y; Shen A
BMC Infect Dis; 2021 Apr; 21(1):330. PubMed ID: 33832459
[TBL] [Abstract][Full Text] [Related]
7. [Study on the resistance of rifampicin-resistant Mycobacterium tuberculosis to anti-tuberculosis drugs in group A].
Dai XW; Li CY; Wang NH; Chen SS; Tian LL; Zhao YF; Tao LY; Yang XY; Ding BC; He XX
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1110-1117. PubMed ID: 37914422
[No Abstract] [Full Text] [Related]
8. Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China.
He W; Liu C; Liu D; Ma A; Song Y; He P; Bao J; Li Y; Zhao B; Fan J; Cheng Q; Zhao Y
J Glob Antimicrob Resist; 2021 Sep; 26():241-248. PubMed ID: 34214699
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: A subsequent study of a national survey.
Wang G; Jiang G; Jing W; Zong Z; Yu X; Chen S; Li W; Huang H
J Infect; 2021 Mar; 82(3):371-377. PubMed ID: 33556430
[TBL] [Abstract][Full Text] [Related]
10. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.
Kabahita JM; Kabugo J; Kakooza F; Adam I; Guido O; Byabajungu H; Namutebi J; Namaganda MM; Lutaaya P; Otim J; Kakembo FE; Kanyerezi S; Nabisubi P; Sserwadda I; Kasule GW; Nakato H; Musisi K; Oola D; Joloba ML; Mboowa G
Antimicrob Resist Infect Control; 2022 May; 11(1):68. PubMed ID: 35550202
[TBL] [Abstract][Full Text] [Related]
11. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.
Xu J; Wang B; Hu M; Huo F; Guo S; Jing W; Nuermberger E; Lu Y
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320727
[TBL] [Abstract][Full Text] [Related]
12. Comparison of
Zong Z; Jing W; Shi J; Wen S; Zhang T; Huo F; Shang Y; Liang Q; Huang H; Pang Y
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844043
[TBL] [Abstract][Full Text] [Related]
13. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K
Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266
[TBL] [Abstract][Full Text] [Related]
14. High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant
Trisakul K; Nonghanphithak D; Chaiyachat P; Kaewprasert O; Sakmongkoljit K; Reechaipichitkul W; Chaiprasert A; Blair D; Clark TG; Faksri K
Emerg Microbes Infect; 2022 Dec; 11(1):1857-1866. PubMed ID: 35792049
[TBL] [Abstract][Full Text] [Related]
15. The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: Observations on surveillance data.
Li S; Tan Y; Deng Y; Bai G; Huang M; Shang Y; Wang Y; Xue Z; Zhang X; Wang W; Pan J; Pang Y
J Infect Public Health; 2024 Jan; 17(1):137-142. PubMed ID: 38000314
[TBL] [Abstract][Full Text] [Related]
16. Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
Disratthakit A; Prammananan T; Tribuddharat C; Thaipisuttikul I; Doi N; Leechawengwongs M; Chaiprasert A
Antimicrob Agents Chemother; 2016 Sep; 60(9):5189-97. PubMed ID: 27297489
[TBL] [Abstract][Full Text] [Related]
17. Bedaquiline, Delamanid, Linezolid, Clofazimine, and Capreomycin MIC Distributions for Drug Resistance
Guo Y; Yang J; Wang W; Wu X; Wan B; Wang H; Sha W; Yu F
Infect Drug Resist; 2023; 16():7587-7595. PubMed ID: 38107433
[TBL] [Abstract][Full Text] [Related]
18. In vitro approaches for generation of Mycobacterium tuberculosis mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants.
Ismail N; Omar SV; Ismail NA; Peters RPH
J Microbiol Methods; 2018 Oct; 153():1-9. PubMed ID: 30165087
[TBL] [Abstract][Full Text] [Related]
19. Delamanid and Bedaquiline Resistance in Mycobacterium tuberculosis Ancestral Beijing Genotype Causing Extensively Drug-Resistant Tuberculosis in a Tibetan Refugee.
Hoffmann H; Kohl TA; Hofmann-Thiel S; Merker M; Beckert P; Jaton K; Nedialkova L; Sahalchyk E; Rothe T; Keller PM; Niemann S
Am J Respir Crit Care Med; 2016 Feb; 193(3):337-40. PubMed ID: 26829425
[No Abstract] [Full Text] [Related]
20. Mutation detection and minimum inhibitory concentration determination against linezolid and clofazimine in confirmed XDR-TB clinical isolates.
Singh K; Sharma S; Banerjee T; Gupta A; Anupurba S
BMC Microbiol; 2022 Oct; 22(1):236. PubMed ID: 36192704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
